Gram-positive bacteria

Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

Retrieved on:

Wednesday, May 12, 2021

Biotechnology, Pharmaceutical, Health, Health, Life sciences, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Orphan drug

b'Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.\nA live audio webcast of the panel will be available under the \xe2\x80\x9cInvestors and News\xe2\x80\x9d section of Seres\xe2\x80\x99 website.

Key Points:

b'Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.\nA live audio webcast of the panel will be available under the \xe2\x80\x9cInvestors and News\xe2\x80\x9d section of Seres\xe2\x80\x99 website.
Seres\xe2\x80\x99 SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA.
The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.
For more information, please visit www.serestherapeutics.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005069/en/\n'

Summit Therapeutics Publishes Scientific Updates to Corporate Website

Retrieved on:

Thursday, May 6, 2021

Medical specialties, Clinical medicine, Gastroenterology, Diarrhea, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Feces, C. Diff

\xc2\xa0It also describes how ridinilazole has, thus far, shown a significant relative sparing of the microbiome compared to the broad-spectrum antibiotics that are the current standard of care for C. diff.

Key Points:

\xc2\xa0It also describes how ridinilazole has, thus far, shown a significant relative sparing of the microbiome compared to the broad-spectrum antibiotics that are the current standard of care for C. diff.
infection.\nClostridioides difficile, or C. difficile, infection (CDI) is a bacterial infection of the colon that produces toxins causing inflammation of the colon and severe watery diarrhea, painful abdominal cramping, nausea, fever, and dehydration.
Accordingly, readers should not place undue reliance on forward-looking statements or information.
The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.\n'

Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at The Aesthetic Meeting 2021

Retrieved on:

Thursday, April 29, 2021

Branches of biology, Collagenase clostridium histolyticum, Gram-positive bacteria, Organ systems, Cellulite, Collagenase, Clostridium, Medical specialties, Injection

If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted.

Key Points:

If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted.
Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.\nIn clinical trials, 84% of subjects treated with QWO experienced injection site bruising.
Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward.
Cellulite: from standing fat herniation to hypodermal stretch marks.Am J Dermatopathol.2000;22(1):34-7.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/endos-qwo-collagenase-clostridiu...\n'

Kanazawa University research: Bacteria in heat--high temperatures facilitate fermentation

Retrieved on:

Tuesday, April 27, 2021

Branches of biology, Corynebacterineae, Gram-positive bacteria, Biology, Academic disciplines, Brewing, Anaerobic digestion, Winemaking, Corynebacterium, Fermentation, Glucose

To-date, fermentation in C. glutamicum is conducted at temperatures of ~30C, wherein the bacterium can grow comfortably.

Key Points:

To-date, fermentation in C. glutamicum is conducted at temperatures of ~30C, wherein the bacterium can grow comfortably.
The researchers started their study by incubating the bacteria with glucose (the primary source of energy) and gradually raising the temperature above 30C.
Optimizing fermentation at high temperatures can not only reduce the risk of contamination from other microbes but also save costs of maintaining cooler conditions.
Elevated, non-proliferative temperatures change the profile of fermentation products in Corynebacterium glutamicum.

Kanazawa University research: Bacteria in heat--high temperatures facilitate fermentation

Retrieved on:

Tuesday, April 27, 2021

Branches of biology, Corynebacterineae, Gram-positive bacteria, Biology, Academic disciplines, Brewing, Anaerobic digestion, Winemaking, Corynebacterium, Fermentation, Glucose

To-date, fermentation in C. glutamicum is conducted at temperatures of ~30C, wherein the bacterium can grow comfortably.

Key Points:

To-date, fermentation in C. glutamicum is conducted at temperatures of ~30C, wherein the bacterium can grow comfortably.
The researchers started their study by incubating the bacteria with glucose (the primary source of energy) and gradually raising the temperature above 30C.
Optimizing fermentation at high temperatures can not only reduce the risk of contamination from other microbes but also save costs of maintaining cooler conditions.
Elevated, non-proliferative temperatures change the profile of fermentation products in Corynebacterium glutamicum.

Rising Meat and Dairy Consumption to Drive Animal Feed Probiotics Sales: Fact.MR

Retrieved on:

Thursday, April 22, 2021

Medical specialties, Lactobacillaceae, Microbiology, Bacteriology, Digestive system, Branches of biology, Probiotic, Gram-positive bacteria, Lactobacillus, Pediococcus, Propionibacterium, Animal feed

Increasing life expectancy and lack of availability of resources for animal feed production are the key factors fueling the demand.

Key Points:

Increasing life expectancy and lack of availability of resources for animal feed production are the key factors fueling the demand.
Growing demand for meat and animal-based protein sources for animal feed is also aiding the growth of the market.\nRising awareness regarding the impact of the increasing consumption of probiotics in animals is a key factor fueling the demand for animal feed probiotics.
Also, growing livestock production has increased the demand for animal feed and animal feed probiotics.\nFor more Insights into the Market, Request a Sample of this Report\n"Manufacturers are investing heavily in the research and development of probiotics products.
The study divulges essential insights on animal feed probiotics market on the basis of source (bacteria, bifidobacterium, enterococcus, lactobacillus, pediococcus, bacillus, propionibacterium, streptococcus, non-bacteria, yeast, fungal and others), animal (companion animals, livestock, poultry, cattle, swine, aquaculture, and other animals), form (liquid and dry), sales channel (modern trade, specialty stores, online retailers, convenience stores, and direct sales), and across major regions of the world (North America, Latin America, Europe, Asia Pacific excluding Japan, and the Middle East & Africa).\nWhat are the key factors driving animal feed probiotics market?\nWhy China is a leading animal feed probiotics market?\nHow is demand for animal feed probiotics market rising?\nWhich is the most preferred sales channel for animal feed probiotics market?\nWhat are the key challenges faced by animal feed probiotics manufacturers?\nWhat is the impact of Covid-19 on animal feed probiotics market?\nNeed more information about Report Methodology?

Rising Meat and Dairy Consumption to Drive Animal Feed Probiotics Sales: Fact.MR

Retrieved on:

Thursday, April 22, 2021

Medical specialties, Lactobacillaceae, Microbiology, Bacteriology, Digestive system, Branches of biology, Probiotic, Gram-positive bacteria, Lactobacillus, Pediococcus, Propionibacterium, Animal feed

Increasing life expectancy and lack of availability of resources for animal feed production are the key factors fueling the demand.

Key Points:

Increasing life expectancy and lack of availability of resources for animal feed production are the key factors fueling the demand.
Growing demand for meat and animal-based protein sources for animal feed is also aiding the growth of the market.\nRising awareness regarding the impact of the increasing consumption of probiotics in animals is a key factor fueling the demand for animal feed probiotics.
Also, growing livestock production has increased the demand for animal feed and animal feed probiotics.\nFor more Insights into the Market, Request a Sample of this Report\n"Manufacturers are investing heavily in the research and development of probiotics products.
The study divulges essential insights on animal feed probiotics market on the basis of source (bacteria, bifidobacterium, enterococcus, lactobacillus, pediococcus, bacillus, propionibacterium, streptococcus, non-bacteria, yeast, fungal and others), animal (companion animals, livestock, poultry, cattle, swine, aquaculture, and other animals), form (liquid and dry), sales channel (modern trade, specialty stores, online retailers, convenience stores, and direct sales), and across major regions of the world (North America, Latin America, Europe, Asia Pacific excluding Japan, and the Middle East & Africa).\nWhat are the key factors driving animal feed probiotics market?\nWhy China is a leading animal feed probiotics market?\nHow is demand for animal feed probiotics market rising?\nWhich is the most preferred sales channel for animal feed probiotics market?\nWhat are the key challenges faced by animal feed probiotics manufacturers?\nWhat is the impact of Covid-19 on animal feed probiotics market?\nNeed more information about Report Methodology?

Reduction of Blood Lipids: A New Era for Cardiovascular Probiotics, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Wednesday, April 7, 2021

Bacteria, Lactobacillaceae, Medical specialties, Gram-positive bacteria, Probiotics, Microbiology, Digestive system, Lactobacillus, Lactic acid bacteria, Lactobacillus paracasei, Lactobacillus acidophilus

Today, there is yet another potent option for the reduction of lipids and improvement in cardiovascular health: a multi-strain, Lactobacillus plantarum KABP formulation known as "Cardio Probiotic".

Key Points:

Today, there is yet another potent option for the reduction of lipids and improvement in cardiovascular health: a multi-strain, Lactobacillus plantarum KABP formulation known as "Cardio Probiotic".
Many strains of lactic acid bacteria (LAB) from the genus Lactobacillus have been identified to possess probiotic properties.
Recent evidence has illustrated the potential of Lactobacillus plantarum KABP for cardiovascular health and lipid metabolism.
For more information, or to register for this event, visit Reduction of Blood Lipids: A New Era for Cardiovascular Probiotics.

Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

Retrieved on:

Wednesday, March 31, 2021

Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Microbiology, Infectious diseases, Staphylococcaceae, Bacterial diseases, Healthcare-associated infections, Gram-positive bacteria, Pathogenic bacteria, Methicillin-resistant Staphylococcus aureus, Staphylococcus aureus, Staphylococcus, ALS-4, Aptorum Group

Enrollment for the first cohort of SAD has been completed and we continue to enroll individuals for other cohorts of the trial.

Key Points:

Enrollment for the first cohort of SAD has been completed and we continue to enroll individuals for other cohorts of the trial.
We are excited to embark on our Phase I trial and are looking forward to completing the trial as swiftly as possible.
As part of Aptorum Groups Acticule infectious disease platform, ALS-4 is a novel first-in-class orally administered small molecule drug based on an anti-virulence approach targeting staphylococcus aureus including MRSA.
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

Study Shows House Wellness Foods’ Breakthrough Feed LP20® Can Advance the Potential of Rivers and Seas to Feed Our Emerging World

Retrieved on:

Tuesday, March 30, 2021

A recently released study on the efficacy of House Wellness Foods Feed LP20 in combating piscine disease factors can be seen as a glimmer of light along the pathway to Vietnams bright future.

Key Points:

A recently released study on the efficacy of House Wellness Foods Feed LP20 in combating piscine disease factors can be seen as a glimmer of light along the pathway to Vietnams bright future.
In summary, researchers fed test stocks a diet supplemented with heat-killed Lactobacillus plantarum, strain L-137, the active ingredient in Feed LP20.
Prior to the present study, Feed LP20 proved its remarkable effectiveness in other aquatic stock, including white leg shrimp and Nile tilapia .
The new study shows the promise of House Wellness Foods Breakthrough Feed LP20, and points to the future of a shared world that is often fragile, yet always filled with hope.